Genmab — Marts 2015
-
21bn USD. JnJ sidder vel fortsat på 50%?
-
af Ibrutinib
-
En anden nyhed fra USA igår var godkendelse af Opdivo i NSCLC (en form for lungekræft) FDA godkendte ansøgningen 5dage (!) efter accept af ansøgning. Det kan pludsligt gå stærkt for Dara...
-
Ja. Godkendt i Malign Melanom i dec14. Resultater i NSCLC i jan15 og nu godkendt i den indikation også
-
Det går pænt stærkt
-
U.S. FDA approves Bristol-Myers immunotherapy for lung cancer
U.S. health regulators on Wednesday swiftly approved a Bristol-Myers Squibb Co drug that helps the immune system fight the most common form of lung cancer, sending the company's shares up more than 5 percent to a multi-year high. The eagerly anticipated Food and Drug Administration approval of the drug known as Opdivo came only about three months after Bristol provided trial results showing that the medicine extended survival in non-small cell lung cancer (NSCLC), one of the biggest markets in oncology. "This approval will provide patients and health care providers knowledge of the survival advantage associated with Opdivo and will help guide patient care and future lung cancer trials," Richard Pazdur, the FDA's head of hematology and oncology product evaluation, said in a statement. Opdivo, known chemically as nivolumab, was approved to treat non-small cell lung cancer after the disease has progressed following platinum-based chemotherapy, typically the first-line treatment against the disease.
Yahoo Finance (finance.yahoo.com)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind